Tariffs and shifting trade dynamics continue to disrupt healthcare and life sciences supply chains. But in addition to affecting operational and commercial outlooks for business, they are also revealing new opportunities for innovators and investors.
In the final article of the series, we explore five key questions:
- What are key areas for investment across the healthcare and life sciences ecosystem?
- Why are joint ventures (JVs) and strategic partnerships the way forward?
- How are regulatory bodies responding to knock-on impacts of tariffs on delayed market entry?
- What does the patent cliff mean for investors and healthcare and life sciences companies?
- What are the opportunities for AI innovation amid trade winds and tariffs?
